{"nctId":"NCT00447382","briefTitle":"Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes","startDateStruct":{"date":"2007-03"},"conditions":["Diabetes","Diabetes Mellitus, Type 1"],"count":330,"armGroups":[{"label":"NN304","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: insulin detemir","Drug: insulin aspart"]},{"label":"NN729","type":"EXPERIMENTAL","interventionNames":["Drug: insulin aspart","Drug: insulin detemir"]}],"interventions":[{"name":"insulin detemir","otherNames":[]},{"name":"insulin aspart","otherNames":[]},{"name":"insulin detemir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 1 diabetes for at least 12 months\n* Basal-bolus treatment for at least 3 months\n* Body Mass Index (BMI) less than or equal to 35.0 kg/m\\^2\n* HbA1c (glycosylated haemoglobin) less than or equal to 12.0%\n\nExclusion Criteria:\n\n* Known or suspected allergy to trial products or related products\n* Pregnancy, breast-feeding or the intention to become pregnant or not using adequate contraceptive measures\n* Receipt of any trial drug within 1 month prior to this trial\n* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation\n* Conditions that may interfere with trial participation as judged by Investigator: proliferative retinopathy or maculopathy requiring acute treatment within the last six months, recurrent major hypoglycaemia, impaired hepatic or renal function, cardiac problems, uncontrolled hypertension (treated and untreated)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Insulin Detemir - Human Insulin Cross-reacting Antibodies","description":"Measured change in concentrations of insulin detemir cross-reacting antibodies and the change ratio from baseline to end of trial was calculated. The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture). The change ratio does not have any unit as it is a ratio.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.81","spread":"0.07"},{"groupId":"OG001","value":"1.89","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Hypoglycaemic Episodes","description":"Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. Hypoglycaemic episodes occurring in the time frame between 23:00 hours (included) and 06:00 hours (excluded) were defined as nocturnal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3215","spread":null},{"groupId":"OG001","value":"2996","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"445","spread":null},{"groupId":"OG001","value":"318","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2741","spread":null},{"groupId":"OG001","value":"2590","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"381","spread":null},{"groupId":"OG001","value":"258","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"472","spread":null},{"groupId":"OG001","value":"404","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Glycaemic Control Parameters (Change in HbA1c)","description":"HbA1c (Glycosylated haemoglobin).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.88","spread":"0.07"},{"groupId":"OG001","value":"7.85","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.07"},{"groupId":"OG001","value":"-0.11","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Glycaemic Control Parameters (Change in Fasting Plasma Glucose [FPG])","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.73","spread":"0.3"},{"groupId":"OG001","value":"9.64","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.3"},{"groupId":"OG001","value":"-0.02","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Glycaemic Control Parameters (9-point Self Measured Plasma Glucose [SMPG])","description":"1. point is Before Breakfast\n2. point is 120 minutes after Breakfast\n3. point is Before Lunch\n4. point is 120 minutes after Lunch\n5. point is Before Dinner\n6. point is 120 minutes after Dinner\n7. point is at Bedtime\n8. point is At 03:00 A.M.\n9. point is Before Breakfast the Following Day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.17","spread":"3.26"},{"groupId":"OG001","value":"8.17","spread":"3.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.95","spread":"3.86"},{"groupId":"OG001","value":"9.03","spread":"3.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.66","spread":"3.36"},{"groupId":"OG001","value":"7.34","spread":"3.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.60","spread":"3.70"},{"groupId":"OG001","value":"8.18","spread":"3.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.29","spread":"3.37"},{"groupId":"OG001","value":"8.16","spread":"3.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.43","spread":"3.37"},{"groupId":"OG001","value":"8.60","spread":"3.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.69","spread":"3.48"},{"groupId":"OG001","value":"8.60","spread":"3.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.97","spread":"3.51"},{"groupId":"OG001","value":"7.72","spread":"3.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.05","spread":"3.49"},{"groupId":"OG001","value":"7.56","spread":"3.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":"3.95"},{"groupId":"OG001","value":"-0.44","spread":"4.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","spread":"4.43"},{"groupId":"OG001","value":"-0.61","spread":"4.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.49","spread":"3.64"},{"groupId":"OG001","value":"0.08","spread":"4.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":"3.82"},{"groupId":"OG001","value":"-0.22","spread":"4.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"4.22"},{"groupId":"OG001","value":"-0.00","spread":"4.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","spread":"4.16"},{"groupId":"OG001","value":"0.07","spread":"4.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","spread":"3.63"},{"groupId":"OG001","value":"0.20","spread":"4.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"4.05"},{"groupId":"OG001","value":"0.08","spread":"4.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":"4.05"},{"groupId":"OG001","value":"0.24","spread":"3.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"4.08"},{"groupId":"OG001","value":"-0.67","spread":"3.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","spread":"4.80"},{"groupId":"OG001","value":"-0.99","spread":"4.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"3.96"},{"groupId":"OG001","value":"-0.28","spread":"4.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"3.98"},{"groupId":"OG001","value":"-0.29","spread":"3.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":"3.80"},{"groupId":"OG001","value":"-0.59","spread":"4.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"4.13"},{"groupId":"OG001","value":"-0.51","spread":"4.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":"3.92"},{"groupId":"OG001","value":"-0.47","spread":"3.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"3.59"},{"groupId":"OG001","value":"-0.31","spread":"3.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.44","spread":"4.14"},{"groupId":"OG001","value":"-0.09","spread":"3.49"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Detemir Specific Antibodies","description":"Measured change in concentrations of antibody values for insulin detemir specific antibodies and the change ratio from the baseline to end of trial was calculated. The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture). The change ratio does not have any unit as it is a ratio.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":"0.04"},{"groupId":"OG001","value":"1.06","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Antibodies","description":"Measured change in concentrations of total insulin antibodies values (the sum of insulin detemir specific and insulin detemir - human insulin cross-reacting antibodies) and the change ratio from baseline to end of trial was calculated. The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture). The change ratio does not have any unit as it is a ratio.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":"0.05"},{"groupId":"OG001","value":"1.55","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Haematology - Basophilis)","description":"Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants.\n\nMeasured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.67"},{"groupId":"OG001","value":"0.36","spread":"0.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.56"},{"groupId":"OG001","value":"0.33","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"0.50"},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Haematology - Eosinophils)","description":"Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.50","spread":"1.27"},{"groupId":"OG001","value":"1.82","spread":"1.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.47","spread":"2.10"},{"groupId":"OG001","value":"2.08","spread":"2.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"2.22"},{"groupId":"OG001","value":"0.00","spread":"3.61"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Haematology - Haemoglobin)","description":"Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.85","spread":"0.92"},{"groupId":"OG001","value":"8.80","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.54","spread":"0.91"},{"groupId":"OG001","value":"8.47","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":"0.52"},{"groupId":"OG001","value":"-0.31","spread":"0.50"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Haematology - Lymphocytes)","description":"Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.\n\nMeasured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.80","spread":"6.94"},{"groupId":"OG001","value":"37.45","spread":"7.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.12","spread":"9.17"},{"groupId":"OG001","value":"36.67","spread":"9.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.25","spread":"9.18"},{"groupId":"OG001","value":"5.33","spread":"6.66"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Haematology - Monocytes)","description":"Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants.\n\nMeasured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.40","spread":"2.17"},{"groupId":"OG001","value":"4.00","spread":"2.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.59","spread":"2.92"},{"groupId":"OG001","value":"3.42","spread":"2.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.50","spread":"1.91"},{"groupId":"OG001","value":"0.67","spread":"0.58"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Haematology - Neutrophils)","description":"Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.\n\nMeasured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.00","spread":"7.51"},{"groupId":"OG001","value":"56.36","spread":"7.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.59","spread":"10.75"},{"groupId":"OG001","value":"57.50","spread":"9.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.25","spread":"10.37"},{"groupId":"OG001","value":"-6.00","spread":"8.66"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Haematology - Thrombocytes)","description":"Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"254.0","spread":"65.5"},{"groupId":"OG001","value":"267.1","spread":"59.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"242.2","spread":"58.3"},{"groupId":"OG001","value":"247.2","spread":"51.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.8","spread":"38.5"},{"groupId":"OG001","value":"-18.6","spread":"38.9"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Haematology - Leucocytes)","description":"Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.\n\nMeasured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.22","spread":"1.91"},{"groupId":"OG001","value":"6.3","spread":"1.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.24","spread":"1.85"},{"groupId":"OG001","value":"5.96","spread":"1.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"1.77"},{"groupId":"OG001","value":"-0.32","spread":"1.69"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Biochemistry - Albumin)","description":"Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.30","spread":"0.23"},{"groupId":"OG001","value":"4.27","spread":"0.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.28","spread":"0.25"},{"groupId":"OG001","value":"4.30","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.21"},{"groupId":"OG001","value":"0.02","spread":"0.20"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Biochemistry - Alanine Aminotransferase [ALAT])","description":"Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.\n\n(ALAT = alanine aminotransferase)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.21","spread":"22.12"},{"groupId":"OG001","value":"25.98","spread":"13.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.72","spread":"25.48"},{"groupId":"OG001","value":"27.81","spread":"16.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"17.80"},{"groupId":"OG001","value":"1.76","spread":"17.17"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Biochemistry - Alkaline Phosphatase [ALP])","description":"Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.\n\n(ALP = alkaline phosphatase)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.40","spread":"23.26"},{"groupId":"OG001","value":"75.55","spread":"25.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.35","spread":"47.20"},{"groupId":"OG001","value":"80.42","spread":"23.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.77","spread":"42.36"},{"groupId":"OG001","value":"4.53","spread":"15.88"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Biochemistry - Creatinine)","description":"Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1","spread":"15.4"},{"groupId":"OG001","value":"72.3","spread":"31.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","spread":"16.4"},{"groupId":"OG001","value":"73.1","spread":"63.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"11.0"},{"groupId":"OG001","value":"0.8","spread":"33.7"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Biochemistry - Lactate Dehydrogenase [LDH])","description":"Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory (LDH = lactate dehydrogenase)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"161.1","spread":"47.8"},{"groupId":"OG001","value":"159.4","spread":"57.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164.9","spread":"62"},{"groupId":"OG001","value":"162.7","spread":"37.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"45"},{"groupId":"OG001","value":"2.6","spread":"46.7"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Biochemistry - Potassium)","description":"Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.46","spread":"0.44"},{"groupId":"OG001","value":"4.37","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.49","spread":"0.49"},{"groupId":"OG001","value":"4.43","spread":"0.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.50"},{"groupId":"OG001","value":"0.06","spread":"0.49"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Biochemistry - Sodium)","description":"Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138.9","spread":"2.6"},{"groupId":"OG001","value":"139.2","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140.3","spread":"2.4"},{"groupId":"OG001","value":"140.0","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"2.8"},{"groupId":"OG001","value":"0.8","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Clinical Laboratory Values (Change in Biochemistry - Total Protein)","description":"Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.23","spread":"0.44"},{"groupId":"OG001","value":"7.24","spread":"0.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.13","spread":"0.44"},{"groupId":"OG001","value":"7.19","spread":"0.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.11","spread":"0.38"},{"groupId":"OG001","value":"-0.06","spread":"0.37"}]}]}]},{"type":"SECONDARY","title":"Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"259","spread":null},{"groupId":"OG001","value":"346","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":164},"commonTop":["Nasopharyngitis","Headache","Influenza","Upper Respiratory Tract Infection"]}}}